On Thrusday 31st we will have the opportunity to learn from the Prof. Axel Guenther (University of Toronto) and from Dr. Tamer Mohamed (Aspect Biosystems Ltd.), the latest results obtained in 3D Printing applied to healthcare overseas and how they envision the future of this technology. Opportunities and limitations in the academia and in the industry.
Dr. Tamer Mohamed, Chief Executive Officer – Aspect Biosystems Ltd.
Tamer Mohamed, CEO, Sam Wadsworth, CSO and Elli Käpylä, Aspect’s Manager of Academic Alliances and Business Development Manager for Europe, she is biomedical engineer and expert scientist in materials and 3D printing and tissue models at Aspect Biosystems. Aspect Biosystems is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. Their company is built on over 10 years of research and development and formed through a collaboration between world-class research groups in Engineering and Medicine at the University of British Columbia. Their proprietary Lab-on- a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. They are focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate drug discovery and development and enable the creation of cutting-edge tissue therapies of the future.
Prof. Axel Goünter, Professor at Faculty of Applied Science & Engineering – University of Toronto
Dr. Guenther is an Associate Professor in the Department of Mechanical and Industrial Engineering, with cross-appointment at the Institute of Biomaterials and Biomedical Engineering at the University of Toronto. He obtained his doctoral degree from ETH Zurich and conducted postdoctoral research at the Massachusetts Institute of Technology. He received the ETH medal (2002), the Ontario Early Researcher Award (2009), the I.W. Smith Award of the Canadian Society of Mechanical Engineers (2010) and the Innovator of the Year Award of the University of Toronto (2013). He co-invented several bioprinting technologies, was previously the Scientific Director of the Centre for Microfluidic Systems in Chemistry and Biology (2008-2018), and the Wallace G. Chalmers Chair of Engineering Design (2012-18). He currently Co-Leads the Canadian Center for Research and Applications in Fluidic Technologies (CRAFT), a collaborative research center between the National Research Council of Canada and the University of Toronto that focuses on device innovation related to the areas of bioprinting, in-vitro diagnostics and organ-on-chip engineering.